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Syphilis is a genital ulcerative disease that facilitates HIV transmission and if untreated during 
pregnancy may lead to fetal infection or perinatal death. In the United States syphilis 
surveillance is based on mandatory reporting from health care providers and laboratories to state 
and local health departments. Recommendations for national syphilis surveillance were 
developed by a group of invited experts who met in Atlanta on March 20-22, 2000. This 
consultation on “Recommendations for Public Health Surveillance of Syphilis in the United 
States” was cosponsored by CDC’s Division of STD Prevention (DSTD), National Center for 
HIV, STD and TB Prevention (NCHSTP); the National Coalition of STD Directors (NCSD); and 
the Council of State and Territorial Epidemiologists (CSTE). The recommendations, which are 
summarized below, were developed for state and local public health programs. The intention of 
this report is to make the collection and reporting of syphilis surveillance data more uniform so 
that data from a variety sources are comparable. 
Case Reporting 
• State and local jurisdictions should adopt the CSTE and CDC surveillance case 
definitions for syphilis to ensure the quality and comparability of surveillance data.1 
• Syphilis cases should be categorized and reported by stage at the time of initial 
examination (which is often the time of initial specimen collection), not at the time of 
treatment or interview.  
• All cases of probable or confirmed syphilis should be reported as morbidity 
regardless of treatment or interview status. Stage determination should be based on 
available clinical and serological information. 
• In the absence of symptom or serology history, sex partners for the last year should 
be evaluated to determine whether the case should be classified as early latent, late 
latent, or latent of unknown duration. 
• The following should be reported to the local health department within one working 
day by public and private providers and laboratories: 
− All probable or confirmed cases of early (primary, secondary or early-
latent infection) syphilis (regardless of treatment status). 
− All reactive, nontreponemal laboratory tests.  
• All confirmatory treponemal test results should be reported when available, but their 
availability should not delay reporting a reactive nontreponemal test result. 
• Health Department Follow-up: 
− Individuals with reactive serologies who are known or suspected of 
having lesions should be contacted for follow-up regardless of age, 
sex, or titer. 
− All women with reactive serologies who are known to be pregnant 
should be contacted for follow-up regardless of age or titer. 
− All women of child-bearing age (less than 45 years of age) with 
reactive serologies should be contacted for follow-up, regardless of 
titer. 
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− All adolescents (< 20 years old) with reactive serologies should be 
contacted for follow-up regardless of titer. 
− Individuals with reactive serologies indicating a four-fold titer increase 
from a previous serology should be contacted for follow-up regardless 
of age or titer. 
• The reactor grid is an administrative tool used to prioritize follow-up of reactive 
serologic tests for syphilis. 
− Reactor grids should be evaluated annually or more frequently if the 
local epidemiology of syphilis changes. 
− Prospective reactor grid evaluations should be completed at least 
every two to three years. 
− In areas with substantial syphilis morbidity, reactor grids should be 
evaluated twice annually to assess the effectiveness and sensitivity of 
the grid. 
Prevalence Monitoring 
• Syphilis prevalence data should be used to assess the yield of specific screening 
activities by identifying the number of new cases detected in relation to the number 
of screening tests performed. In addition to screening assessments, syphilis 
prevalence monitoring at local, state, and national levels should be used to: 
− monitor disease burden and trends  
− identify populations with high rates of infection 
− evaluate case-report surveillance data 
Data Analyses and Dissemination 
• In areas with substantial morbidity, surveillance data should be analyzed at least 
monthly to monitor changes in incidence or new patterns of disease.  
• In low morbidity areas, cases should be reviewed as reports are received and a 
monthly overview should be routinely completed to monitor changes in incidence or 
patterns of disease. 
• At a minimum, data should be analyzed by demographic and risk behavior 
characteristics, including gender of sex partners. 
• A plan for regular dissemination of information derived from the analysis of syphilis 
case-reported data and prevalence data should be developed at local, state, and 
national levels. 
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Introduction 
In 1999, the Division of Sexually Transmitted Disease Prevention (DSTD) at the Centers for 
Disease Control and Prevention (CDC) announced a national plan to eliminate syphilis from the 
United States.2 The national plan established specific goals of reducing the number of primary 
and secondary syphilis cases to 1,000 or fewer and increasing the number of syphilis-free 
counties to 90% by 2005. The national plan outlines five strategies critical to achieve 
elimination: 1) enhanced surveillance, 2) strengthened community involvement and 
partnerships, 3) rapid outbreak response, 4) expanded clinical and laboratory services and 5) 
enhanced health promotion. 
In response to the national plan, and particularly, the inclusion of “enhanced surveillance” as 
a cross-cutting strategy, a national meeting was sponsored in March of 2000 by the DSTD/CDC, 
the National Coalition of STD Directors (NCSD), and the Council of State and Territorial 
Epidemiologists (CSTE) to develop guidelines for syphilis surveillance. Meeting consultants 
included representatives from the 32 CDC funded syphilis elimination sites and representatives 
from NCSD and CSTE. Consultants were assigned to one of five workgroups formed to address 
the following issues: 1) case reporting, 2) prevalence monitoring, 3) congenital syphilis, 4) active 
surveillance and outbreak detection and 5) behavioral and social surveillance. Key questions 
were developed for each workgroup, and consultants were provided background materials 
(e.g.,published manuscripts, abstracts, and material presented at professional meetings) in 
advance of the meeting to help them address the key questions. Recommendations were 
developed based on the workgroups’ responses to the key questions. 
While surveillance must be tailored to the level of syphilis morbidity in a given jurisdiction, an 
important objective for national syphilis surveillance is to assure consistency of surveillance 
practices among states. In communities where syphilis has been absent for years, the focus of 
surveillance should be the identification of clinical symptomatic syphilis (primary syphilis 
presenting as genital ulcer disease or secondary syphilis presenting as rash). For such a focus, 
public health officials need to enlist the support of practicing clinicians who will be the first to see 
such cases. In such communities, serologic surveillance is not likely to be a particularly efficient 
approach. For those communities with continuing endemic syphilis, expanding serologic 
screening to high-risk populations and implementing or enhancing many of the traditional 
surveillance and control activities are essential. 
This report provides updated syphilis surveillance guidelines for health department personnel 
to use in improving and developing syphilis surveillance techniques. Although reporting syphilis 
cases is mandated by state laws and regulations in the United States, and information about 
syphilis cases is reported to CDC from all states and territories, the usefulness of surveillance 
data has been limited by the lack of uniform public health surveillance practices. The intention of 
this report is to make the collection and reporting of syphilis surveillance data more uniform so 
that data from a variety sources are comparable. 
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General Principles 
Components of Syphilis Surveillance 
Surveillance for syphilis has two main components: 
• Case reporting: the process of reporting cases (or reactive serologic laboratory 
results) of notifiable infectious diseases by providers or laboratories to local and state 
health departments and from state health departments to CDC. 
• Prevalence monitoring: monitoring trends in prevalence in defined populations over 
time, where prevalence is the proportion of persons in a population that has the 
disease or condition at a specified point in time.  
In contrast to case reporting, which is intended to be population-based, prevalence monitoring 
for syphilis is generally performed using data obtained from selected populations. Prevalence 
data are usually collected systematically from routine screening rather than from special studies 
performed for the primary purpose of assessing disease burden. The specific purposes of case 
reporting and prevalence monitoring are discussed in the following section, and the selection of 
priority populations for monitoring prevalence is discussed later in this report.  
Purposes and Uses of Syphilis Surveillance 
Public health surveillance is the ongoing and systematic collection, analysis, and interpretation 
of health data in the process of describing and monitoring a health event.3 Surveillance data are 
useful for a variety of reasons, including the planning, implementation, and evaluation of public 
health programs and interventions. Syphilis surveillance data have traditionally relied on case 
reporting from providers and laboratories. Prevalence monitoring data for syphilis and other 
STDs have provided an additional perspective on disease occurrence in some populations. 
Behavioral and social surveillance data have been used to identify and monitor risk exposures of 
at-risk and infected populations. 
Case Reporting 
The purposes and uses of syphilis surveillance using case-reporting data at local, state, and 
national levels are:  
• to monitor rates and trends of infection; 
• to identify outbreaks rapidly; 
• to identify persons at high risk for syphilis and the affected communities in which 
they live; 
• to identify characteristics of infected persons and generate hypotheses regarding risk 
factors; 
• to identify gaps in health care and missed opportunities for interventions; 
• to demonstrate the need for funding of syphilis control programs; 
• to design and target interventions. 
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At the local and state levels, case-reporting data should be used: 
• to identify major providers or major laboratories that are or are not testing or 
reporting; 
• to assure proper diagnosis, treatment, and partner management for all persons with 
early syphilis; 
• to identify persons at risk for HIV infection; 
• to assess the effectiveness of syphilis prevention and control programs; 
• to assess patient management (ensure proper evaluation and treatment of persons 
with syphilis); 
• to evaluate the effectiveness of prenatal syphilis screening in preventing congenital 
syphilis. 
Monitor rates and trends of infection. Data obtained from case reports provide a 
minimum estimate of the burden of syphilis in the general population. The usefulness of these 
data for monitoring trends in disease burden is limited by three factors: a) the proportion of 
infected persons who seek medical attention because of symptoms; b) the extent to which the 
number and characteristics of asymptomatic persons screened remain stable over time; and c) 
the variability of reporting by providers and laboratories. 
Identify outbreaks rapidly. An important use of case-reported data is determining whether 
increases in numbers of cases suggests an outbreak of disease that requires immediate 
investigation.  
Identify persons at high risk for syphilis and the affected communities in which 
they live. Analyses of case-report data indicate that rates of syphilis vary by age, race or 
ethnicity, geographic place of residence, and type of health-care provider. These data should be 
used to identify persons at increased risk for syphilis infection and to develop interventions and 
screening criteria. 
Identify characteristics of infected persons and generate hypotheses regarding risk 
factors. Information collected routinely through case reporting often provides valuable 
epidemiologic information with regard to the “person, place, and time” links that help identify 
characteristics of infected persons and aid in generating hypotheses. 
Identify gaps in health care and missed opportunities for interventions. Information 
on prenatal care, testing, treatment, and follow up should be collected in case reports of early 
syphilis and congenital syphilis to allow local areas to identify gaps in care, to assess availability 
and use of these services for men and women at high risk of acquiring syphilis, and to develop 
informative programs for providers and outreach activities targeting high-risk populations. 
Demonstrate the need for funding syphilis control programs. Surveillance data 
obtained through case reports may be used to demonstrate the need for continued or increased 
funding of syphilis prevention and control programs.  
Identify major providers and laboratories that are or are not testing or reporting. 
Many state and local STD prevention programs maintain a registry of licensed laboratories and 
providers. Periodic analyses of syphilis case-reporting data by both providers and laboratories 
can identify variations in reporting that may require intervention by the health department. 
Providers and laboratories that do not report syphilis cases or that do not participate in efforts to 
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monitor syphilis prevalence can be identified by comparing the registries with information from 
case-reporting and prevalence-monitoring systems. Those providers and laboratories not testing 
or reporting should be contacted. 
Assure proper diagnosis, treatment, and partner management for all cases of early 
syphilis. At local and state levels, STD prevention programs need to contact persons infected 
with syphilis or the reporting health care provider to ensure that patients with early syphilis are 
staged correctly, treated with appropriate therapy, offered partner-management services to 
prevent reinfection from and additional transmission by sex partners, and to ensure that exposed 
contacts are evaluated and treated appropriately. 
Identify persons at increased risk for HIV infection. Persons infected with primary 
syphilis have an increased risk of acquiring HIV infection, and persons infected with HIV who 
are co-infected with primary syphilis are more likely to transmit HIV.4 A diagnosis of syphilis is 
also an indication that the infected individual has had unprotected sexual contact with at least 
one other person. Consequently, case reporting can help identify individuals and population 
subgroups that may also be at high risk for HIV infection. This would assist health department 
personnel in their efforts to focus prevention and intervention activities. 
Assess the effectiveness of syphilis prevention and control programs. Trends in 
reported cases may provide one measure of the effectiveness of disease control programs.3  
Careful analyses of specific disease control initiatives using reported cases over time as an 
outcome measure may provide a sensitive assessment of the effectiveness of specific 
interventions. However, consideration of social, behavioral, and other secular trends is important 
when interpreting data for this purpose. 
Prevalence Monitoring 
Syphilis prevalence data have traditionally been used to assess the yield of specific screening 
initiatives by identifying the number of new cases detected in relation to the number of screening 
tests performed. In addition to screening assessments, the purposes and uses of syphilis 
prevalence monitoring at local, state, and national levels are:  
• to monitor disease burden and trends; 
• to identify populations with high rates of infection; 
• to evaluate case-reporting surveillance data; 
• to design and target interventions; 
• to allocate public health resources. 
Monitor disease burden and trends. A primary objective of surveillance is to monitor the 
occurrence of disease over time within specific populations. Prevalence-monitoring data can be 
used to estimate the prevalence of disease in specific populations that are routinely screened for 
syphilis. Disease trends in specific populations can often be measured with greater accuracy by 
using prevalence-monitoring data than by using data from case reports because the screened 
populations are better defined. Trends in prevalence in the population(s) screened may provide 
insight into trends in similar populations in the community. 
Identify populations with high rates of infection. Prevalence data for syphilis suggest 
that demographic and behavioral characteristics are associated with a high prevalence of 
syphilis. Therefore, prevalence monitoring may be useful in developing syphilis control and 
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intervention programs. However, it may not be possible to generalize the results to populations 
for which no prevalence data exist.  
Evaluate case-reporting data. Prevalence data provide an accurate measure of 
disease prevalence within the screened population. Prevalence data are less likely to be 
biased by the under-reporting inherent in case-reporting data. Under-reporting can result in 
biased estimates of disease occurrence when case-reporting data are used alone. Substantial 
variation between estimates based on case reporting and estimates based on prevalence data 
within defined populations may indicate inadequate reporting or screening, or both. 
Design and target interventions. Prevalence data can provide information on populations 
at increased risk for STD acquisition and transmission. Information on risk factors for acquiring 
STDs may also be obtained from prevalence-monitoring data. Data about high-risk populations 
and associated risk factors may be used to develop prevention and intervention programs.  
Allocate public health resources. Prevalence-monitoring data may be used by STD 
prevention programs in their efforts to obtain funding for syphilis control and intervention 
programs.  
Case Definitions 
State and local jurisdictions should adopt the following CSTE and CDC surveillance case 
definitions for syphilis to ensure the quality and comparability of surveillance data. 
Syphilis infections should be categorized and reported by stage at the time of initial 
examination (which is often the time of initial specimen collection), not at the time of treatment 
or interview. 
All cases of probable and confirmed syphilis meeting the case definitions should be reported 
as morbidity regardless of treatment or interview status. Stage determination should be based on 
available clinical and serological information, i.e., documented signs or symptoms of primary or 
secondary syphilis or evidence of an epidemiological link (named contact to primary or 
secondary case) or history of a negative serologic test for syphilis within the past year. 
In the absence of symptom or serology history, sex partners for the last year should be 
evaluated to determine whether the case is classified as early latent, late latent, or latent of 
unknown duration. 
Syphilis Case Definitions (All Definitions Revised 9/96)1 
Syphilis is a complex sexually transmitted disease that has a highly variable clinical course. 
Classification by a clinician with expertise in syphilis may take precedence over the following 
case definitions developed for surveillance purposes. 
Syphilis, primary 
Clinical description 
A stage of infection with Treponema pallidum characterized by one or more chancres (ulcers); 
chancres might differ considerably in clinical appearance. 
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Laboratory criteria for diagnosis 
• Demonstration of T. pallidum in clinical specimens by darkfield microscopy, direct 
fluorescent antibody (DFA-TP), or equivalent methods 
Case classification 
Probable: a clinically compatible case with one or more ulcers (chancres) consistent with 
primary syphilis and a reactive serologic test (nontreponemal: Venereal Disease Research 
Laboratory [VDRL] or rapid plasma reagin [RPR]; treponemal: fluorescent treponemal antibody 
absorbed [FTA-ABS] or microhemagglutination assay for antibody to T. pallidum [MHA-TP]) 
Confirmed: a clinically compatible case that is laboratory confirmed 
Syphilis, secondary 
Clinical description 
A stage of infection caused by T. pallidum and characterized by localized or diffuse 
mucocutaneous lesions, often with generalized lymphadenopathy. The primary chancre may still 
be present. 
Laboratory criteria for diagnosis 
• Demonstration of T. pallidum in clinical specimens by darkfield microscopy, DFATP, 
or equivalent methods 
Case classification 
Probable: a clinically compatible case with a nontreponemal (VDRL or RPR) titer >4 
Confirmed: a clinically compatible case that is laboratory confirmed 
Syphilis, latent 
Clinical description 
A stage of infection caused by T. pallidum in which organisms persist in the body of the 
infected person without causing symptoms or signs. Latent syphilis is subdivided into early, late, 
and unknown categories based on the duration of infection. 
Case classification 
Probable: no clinical signs or symptoms of syphilis and the presence of one of the following: 
• No past diagnosis of syphilis, a reactive nontreponemal test (i.e., VDRL or RPR), and 
a reactive treponemal test (i.e., FTA-ABS or MHA-TP) 
• A past history of syphilis therapy and a current nontreponemal test titer 
demonstrating fourfold or greater increase from the last nontreponemal test titer 
Syphilis, early latent 
Clinical description 
A subcategory of latent syphilis. When initial infection has occurred within the previous 12 
months, latent syphilis is classified as early latent. 
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Case classification 
Probable: latent syphilis (see Syphilis, latent) in a person who has evidence of having acquired 
the infection within the previous 12 months based on one or more of the following criteria: 
• Documented seroconversion or fourfold or greater increase in titer of a 
nontreponemal test during the previous 12 months 
• A history of symptoms consistent with primary or secondary syphilis during the 
previous 12 months 
• A history of sexual exposure to a partner who had confirmed or probable primary or 
secondary syphilis or probable early latent syphilis (documented independently as 
duration <1 year) 
• Reactive nontreponemal and treponemal tests from a person whose only possible 
exposure occurred within the preceding 12 months 
Syphilis, late latent 
Clinical description 
A subcategory of latent syphilis. When initial infection has occurred >1 year previously, 
latent syphilis is classified as late latent. 
Case classification 
Probable: latent syphilis (see Syphilis, latent) in a patient who has no evidence of having 
acquired the disease within the preceding 12 months (see Syphilis, early latent) and whose age 
and titer do not meet the criteria specified for latent syphilis of unknown duration. 
Syphilis, latent, of unknown duration 
Clinical description 
A subcategory of latent syphilis. When the date of initial infection cannot be established as 
having occurred within the previous year and the patient’s age and titer meet criteria described 
below, latent syphilis is classified as latent syphilis of unknown duration. 
Case classification 
Probable: latent syphilis (see Syphilis, latent) that does not meet the criteria for early latent 
syphilis, and the patient is aged 13–35 years and has a nontreponemal titer >32 
Neurosyphilis 
Clinical description 
Evidence of central nervous system infection with T. pallidum 
Laboratory criteria for diagnosis 
• A reactive serologic test for syphilis and reactive VDRL in cerebrospinal fluid (CSF)  
Case classification 
Probable: syphilis of any stage, a negative VDRL in CSF, and both the following: 
• Elevated CSF protein or leukocyte count in the absence of other known causes of 
these abnormalities 
• Clinical symptoms or signs consistent with neurosyphilis without other known causes 
for these clinical abnormalities 
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Confirmed: syphilis of any stage that meets the laboratory criteria for neurosyphilis 
Syphilis, late, with clinical manifestations other than neurosyphilis (late benign 
syphilis and cardiovascular syphilis) 
Clinical description 
Clinical manifestations of late syphilis other than neurosyphilis may include inflammatory 
lesions of the cardiovascular system, skin, and bone. Rarely, other structures (e.g., the upper and 
lower respiratory tracts, mouth, eye, abdominal organs, reproductive organs, lymph nodes, and 
skeletal muscle) may be involved. Late syphilis usually becomes clinically manifest only after a 
period of 15–30 years of untreated infection. 
Laboratory criteria for diagnosis 
Demonstration of T. pallidum in late lesions by fluorescent antibody or special stains 
(although organisms are rarely visualized in late lesions) 
Case classification 
Probable: characteristic abnormalities or lesions of the cardiovascular system, skin, bone, or 
other structures with a reactive treponemal test, in the absence of other known causes of these 
abnormalities, and without CSF abnormalities and clinical symptoms or signs consistent with 
neurosyphilis 
Confirmed: a clinically compatible case that is laboratory confirmed 
Comment 
Analysis of CSF for evidence of neurosyphilis is necessary in the evaluation of late syphilis 
with clinical manifestations. 
Syphilitic Stillbirth 
Clinical description 
A fetal death that occurs after a 20-week gestation or in which the fetus weighs >500 g and 
the mother had untreated or inadequately treated* syphilis at delivery 
Comment 
For reporting purposes, syphilitic stillbirths should be reported as cases of congenital 
syphilis. 
Syphilis, Congenital  
Clinical description 
A condition caused by infection in utero with Treponema pallidum. A wide spectrum of 
severity exists, and only severe cases are clinically apparent at birth. An infant or child (aged <2 
years) may have signs such as hepatosplenomegaly, rash, condyloma lata, snuffles, jaundice 
(nonviral hepatitis), pseudoparalysis, anemia, or edema (nephrotic syndrome and/or 
malnutrition). An older child may have stigmata (e.g., interstitial keratitis, nerve deafness, 
anterior bowing of shins, frontal bossing, mulberry molars, Hutchinson teeth, saddle nose, 
rhagades, or Clutton joints). 
 
_______________ 
*Inadequate treatment consists of any nonpenicillin therapy or penicillin administered <30 days 
before delivery. 
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Laboratory criteria for diagnosis 
Demonstration of T. pallidum by darkfield microscopy, fluorescent antibody, or other 
specific stains in specimens from lesions, placenta, umbilical cord, or autopsy material 
Case classification 
Probable: a condition affecting an infant whose mother had untreated or inadequately 
treated* syphilis at delivery, regardless of signs in the infant, or an infant or child who has a 
reactive treponemal test for syphilis and any one of the following: 
• Any evidence of congenital syphilis on physical examination 
• Any evidence of congenital syphilis on radiographs of long bones 
• A reactive cerebrospinal fluid (CSF) venereal disease research laboratory (VDRL) 
• An elevated CSF cell count or protein (without other cause) 
• A reactive fluorescent treponemal antibody absorbed—19S-IgM antibody test or IgM 
enzyme-linked immunosorbent assay 
Confirmed: a case that is laboratory confirmed 
Comment 
Congenital and acquired syphilis may be difficult to distinguish when a child is seropositive 
after infancy. Signs of congenital syphilis may not be obvious, and stigmata may not yet have 
developed. Abnormal values for CSF VDRL, cell count, and protein, as well as IgM antibodies, 
may be found in either congenital or acquired syphilis. Findings on radiographs of long bones 
may help because radiographic changes in the metaphysis and epiphysis are considered classic 
signs of congenitally acquired syphilis. The decision may ultimately be based on maternal history 
and clinical judgment. In a young child, the possibility of sexual abuse should be considered as a 
cause of acquired rather than congenital syphilis, depending on the clinical picture. For reporting 
purposes, congenital syphilis includes cases of congenitally acquired syphilis among infants and 














*Inadequate treatment consists of any nonpenicillin therapy or penicillin administered <30 days 
before delivery. 
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Case Reporting 
Sources of Case and Serology Reports 
Health departments should accept case reports of syphilis infection and reactive syphilis 
laboratory tests from clinicians and laboratories. Although laboratory-based reporting is 
essential, clinicians should continue to be encouraged to report cases of syphilis. Health 
departments should maintain the authority to contact clinicians directly for demographic, 
medical, and risk information. 
• Public and private providers should, within one working day of diagnosis, report 
probable or confirmed cases of early (primary, secondary or early-latent infection) 
syphilis to the health department. 
• Public and private providers should report all other stages of syphilis in accordance 
with state notifiable disease statutes and regulations. 
• Public and private providers should report reactive syphilis tests in pregnant women 
within one working day to the local health department so that the department can 
ensure appropriate treatment and follow-up of all pregnant women. 
• Public and private laboratories should, within one working day of test result, report 
positive, nontreponemal tests. Associated treponemal test results should be reported 
when available, but their availability should not delay reporting a reactive 
nontreponemal test result.  
Reporting Formats and Intervals 
Uniform reporting formats and intervals should be adopted by STD prevention programs. 
• Local health department syphilis surveillance data should be reported electronically, 
in line-listed format, to state health departments to improve local disease-control 
capacity and to promote integration of local surveillance data management and 
analysis activities. Electronic systems should be established that facilitate frequent 
analysis of local and statewide data.  
• All state STD prevention programs should be capable of reporting electronic, line-
listed syphilis case reports to the Epidemiology Program Office (EPO) at CDC 
weekly. At the request of STD prevention programs, CDC should provide technical 
assistance to facilitate the transition to electronic systems. 
• States should submit congenital syphilis case reports to CDC using a CDC-
compatible system at least monthly.  
• State STD prevention personnel should coordinate the transmission of STD data to 
CDC with data for other diseases that need to be reported by the state. 
• State and local STD-control programs should develop the information management 
capacity to support electronic STD surveillance case reporting to CDC and should 
become capable of receiving data electronically from providers and laboratories.  
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Reactor Grid Analysis 
In contrast to many other infectious diseases, in which a positive diagnostic test generally 
indicates active infection, the likelihood that a reactive serological test for syphilis (STS) indicates 
active, untreated infection may be related to the titer and age of the patient. Because the 
resources necessary to conduct case investigations are frequently limited, especially in high 
morbidity areas, health departments often develop guidelines to ensure that disease intervention 
is worthwhile and effective. On the basis of such guidelines, some health departments choose 
not to evaluate or contact individuals whom they determine to be at low risk of having or 
transmitting active disease. As a result, older men and women, or persons with low titers may 
not be contacted, evaluated or reported. The administrative tool used to make this 
determination is generally referred to as a “reactor grid” and may include the age, sex, and 
nontreponemal serum assay titer. Regardless of local priorities and guidelines, positive STS 
should be evaluated for all persons in the following situations: 
• Individuals with reactive serologies who are known or suspected of having lesions 
should be contacted for follow-up regardless of age, sex, or titer. 
• All women known to be pregnant should be contacted for follow-up regardless of age 
or titer. 
• All women of child-bearing age (less than 45 years of age) should be contacted for 
follow-up, regardless of titer. 
• All adolescents (< 20 years old) should be contacted for follow-up regardless of titer. 
• Individuals with reactive serologies indicating a four-fold titer increase (two tube 
dilution) from a previous serology should be initiated for follow-up regardless of age 
or titer. 
Age, sex, and titer do not define the stage of infection or infectiousness of a person, and, 
depending on the local epidemiology of disease, relationships between these factors and 
infection may change over time. Therefore, reactor grids should be periodically evaluated at the 
local or state levels. In general, reactor grids should be adjusted to increase their sensitivity in 
identifying infectious persons. 
Reactor grid evaluation should be based on local data. In general there are two approaches 
for evaluating reactor grids: prospective and retrospective analyses. Prospective evaluations are 
more accurate and they involve “opening up” all or part of the reactor grid for a specified time 
period and assessing all reported reactive tests to determine the yield of early syphilis for each 
sex, titer, and age category. Using this method, a “yield threshold” is determined based on 
program resources. Grid categories (sex, titer, and age combinations) where the yield of 
infectious or early syphilis falls below the designated threshold may be considered for 
“administrative closure” (i.e., cases that fall into these categories are not followed up).  
Retrospective analyses may be conducted by a variety of methods. In general, this approach 
involves analyzing existing surveillance data (case-reporting or prevalence-monitoring) to 
determine which sex, titer, and age categories are least likely to yield infectious or early syphilis. 
Populations appropriate for retrospective analysis are those in which all individuals with reactive 
STS are followed. Care should be taken to ensure that retrospective analyses of reactor grids are 
not biased due to the exclusion of individuals with reactive serologies in a defined population 
and time period. 
• Reactor grids should be evaluated annually or more frequently if the local 
epidemiology of syphilis changes. 
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• Prospective reactor grid evaluations should be completed at least every two to three 
years. 
• In areas with substantial morbidity, reactor grids should be evaluated twice annually 
to assess the effectiveness and sensitivity of the grid. 
Provider-Based Case Reporting 
Although all states have mandated that health care providers report all cases of syphilis, in 
fact, most reported syphilis cases are identified through laboratory reporting. The prompt 
identification of persons likely to have acquired syphilis recently (e.g., symptomatic persons 
presenting for care with primary or secondary syphilis) is particularly important for interrupting 
disease transmission. The following recommendations are intended to increase the prompt 
identification and reporting of infectious cases of syphilis. 
A national standard, outlined in the National Plan to Eliminate Syphilis from the United 
States, recommends that “public and private providers will within one working day of diagnosis, 
report presumptive or confirmed cases of early syphilis to the health department.”2 In addition, 
local and state STD prevention programs need to interact with providers to ensure that the 
diagnosis, treatment, and management of each case is appropriate. To accomplish these goals, it 
is essential that health departments do the following: 
• Publicize reporting statutes or regulations that include early syphilis as a 
communicable disease priority (e.g., it must be reported within one working day of 
diagnosis). 
• Distribute a written protocol to providers outlining responsibilities and procedures for 
reporting syphilis cases and procedures for communicating with health departments. 
• Develop a plan to work with health care provider licensure and accreditation 
organizations to encourage providers to report notifiable conditions. 
• Develop and implement a system to communicate and directly interact with large 
groups of health care providers and professional associations which can be notified 
of outbreaks and changes in the local epidemiology of syphilis and  can help to 
increase compliance with reporting requirements. Such a system should enable 
health department personnel to: 
− identify and visit providers who report a large number of cases. 
− identify and visit providers who fail to report syphilis cases (by 
matching laboratory reports to health care provider reports). 
− identify and visit providers who care for persons living in 
communities with high rates of syphilis. 
− establish a listserv or e-mail communication to increase and improve 
communication with providers. 
− provide feedback to reporting providers about individual cases 
regardless of stage, informing them about the clinical manifestations 
and public health implications of the disease and emphasizing the 
important role they play in preventing its transmission.  
− identify a health department employee to serve as a liaison to the 
providers in the community. 
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• Develop the flexibility to receive syphilis case reports through a variety of 
mechanisms, including toll-free telephone numbers, facsimile machines, direct 
electronic reporting methods, and internet-based systems. 
Laboratory-Based Case Reporting 
While states have mandated that providers and laboratories report all reactive serologic tests 
for syphilis, some states do not enforce adherence to this requirement. When there is incomplete 
reporting by both providers and laboratories, marked under-reporting of diagnosed syphilis 
cases may take place.  
The National Plan to Eliminate Syphilis indicates that “public and private laboratories will 
within one working day of test result, report positive tests that are quantified by titer.”  To 
achieve this standard, sufficient resources should be mobilized that enable laboratories to report 
promptly, and a laboratory communication plan should be developed that may include the 
following: 
• State and local STD prevention programs should have a written protocol that 
outlines health departments’ procedures for interacting with laboratories and the 
laboratories’ responsibilities and procedures for syphilis case reporting. 
• Where feasible, state and local STD prevention programs should work with 
laboratory licensure and accreditation organizations to encourage reporting of 
notifiable conditions as required by statute. 
• The STD program should also maintain relations with laboratories to ensure 
compliance with reporting requirements. As part of these activities, a program 
should: 
− identify key laboratories [e.g., those that report a large number of 
serologic test for syphilis (STS), and large laboratories that rarely 
report]. 
− maintain and update regularly a registry of laboratories within and 
outside of the local area or state that perform a significant number of 
STS for the local area or state. 
− visit laboratories, at least annually, that perform a large number of 
tests to assess the timeliness and completeness of reporting. 
− regularly provide reports back to laboratories to inform them of the 
number of STS that have been performed and the number of 
reactive STS that they reported.  
− establish a listserv or e-mail communication to increase and improve 
communication between laboratories and the STD program. 
− maintain correspondence with local and state professional 
associations that represent laboratories. 
− visit sites to review reporting rules with key, large-volume laboratories 
within and outside of their jurisdictions. 
− identify a public health department employee who may serve as a 
liaison to the area’s laboratories. 
− provide multiple methods to receive serologic reports, including toll-
free telephone numbers, facsimile machines, direct electronic 
reporting, and internet-based systems. 
− implement methods to monitor an individual laboratory’s changes in 
reporting practices. 
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− promote the adoption of statutes or regulations to require laboratory 
reporting of the titer of reactive nontreponemal serology tests within 
one working day of the test result and without waiting for the 
completion of confirmatory testing. 
Evaluating Laboratory-Based Reporting 
Laboratory reporting of serologic test results is a critical component of syphilis surveillance. 
Laboratory reporting evaluation programs enable STD prevention programs to periodically 
evaluate the syphilis testing activities and reporting practices of laboratories to ensure prompt 
and complete laboratory-based reporting of possible cases. 
Addressing the components of a program to evaluate reporting by laboratories can enhance 
STD surveillance (Box 1). Activities by STD program staff should also be assessed in all 
laboratory evaluation visits (Box 2). 
Box 1. Components of a Laboratory Reporting Evaluation 
 Program to Improve Syphilis Surveillance 
1. Coordinate Laboratory Evaluations 
• Identify a laboratory evaluation coordinator. 
• Develop and maintain a registry of all laboratories that perform syphilis 
diagnostic testing for providers in the STD program’s jurisdiction. 
• Periodically prioritize laboratories for evaluation (e.g., laboratories that 
serve areas with substantial morbidity or laboratories that do report or 
should report substantial numbers of persons with reactive STS).  
• Develop a schedule for evaluating laboratories (priority laboratories 
should be evaluated at least annually). 
2. Develop Evaluation Criteria 
• Evaluation criteria should be developed by setting action levels that 
define acceptable levels of reporting completeness and timeliness. 
• Define corrective actions that will be taken when the laboratory’s 
reporting performance falls below the defined action levels. 
3. Determine a Time Period and Sampling Strategy for Evaluation 
• The time period for evaluation will be retrospective (to account for 
reporting lag), and its duration will depend on the test volume of the 
laboratory (higher volume implies shorter sampling period). Reviewing a 
sample of STS results in which a minimum of 50 are positive should be 
adequate to calculate completeness and timeliness of reporting. 
4. Laboratory Evaluation Visit 
• The laboratory evaluation coordinator should train and monitor field 
staff to ensure that laboratory evaluations are conducted in a consistent, 
complete, timely, and professional manner (see Box 2). 
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Data Collection 
The laboratory evaluation coordinator must develop a uniform format for the collection of 
information during the laboratory visit. A sample format is included in Appendix 1. The 
minimum data required are: 
• time period evaluated; 
• total number of STS performed (by test type and sex); and 
• number of reactive STS (by test type and sex). 
Assessment of the Sensitivity of Laboratory Reporting 
The proportion of reactive STS reported by the laboratory to the STD Program, or the 
sensitivity of reporting from that laboratory, is calculated by dividing the total number of reactive 
STS that the laboratory reports by the number of reactive STS processed by the laboratory 
during the designated time period. Out-of-jurisdiction reporting may be an issue for some project 
areas and should be considered when calculating the sensitivity of reporting. 
Assessment of Timeliness of Laboratory Reporting  
Timeliness is a measure of the delay between any two (or more) steps in the surveillance 
system.5 Timeliness of reporting is usually measured in days or weeks. The allowable time frame 
for reporting is often outlined in state communicable disease reporting statutes and varies from 
state to state.  
• A sample of reactive STS reports should be evaluated to determine the date when 
specimens were analyzed by the laboratory and the date when reports were received 
by the STD Program. Laboratory reports should be date stamped by health 
department personnel upon receipt. 
• The lag time in days between analysis of the specimen by the laboratory and receipt 
of the report by the STD program needs to be calculated for a sample of serologic 
reports and compared to the state specific reporting requirements. 
• Adding up the “days until report received” for all tests reviewed and dividing  by the 
number of tests reviewed yields the mean lag time between analysis of specimen by 
a laboratory and receipt of reports from the laboratory by the STD program. Other 
options for measuring timeliness include calculating the range and median reporting 
delays or calculating the proportion of serologic reports received within a variety of 
day increments (e.g., 0 to 3 days, 4 to 7 days, 8 to 14 days, and greater than 14 
days). 
Laboratory Evaluation Feedback 
• The laboratory evaluation coordinator should inform the laboratory director in 
writing of the results of each evaluation visit within one month of the visit. If the 
sensitivity or timeliness of reporting are below established action levels, a 
collaborative improvement plan should be devised. 
• STD programs should distribute STD surveillance reports (including results of 
laboratory-based surveillance and summary findings from laboratory reporting 
evaluations) to all laboratories on an annual basis at a minimum. 
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• The laboratory evaluation coordinator should maintain records of laboratory 
evaluations, including data concerning the completeness and timeliness of reporting 
and document all feedback given to laboratories. 
• A summary of the evaluation findings should be provided to the laboratory outlining 
strengths, deficiencies, and plans for improvement. 
 
Box 2. Responsibilities of STD-Control Program Staff During Laboratory 
Reporting Evaluation Visits 
1. Before the Laboratory Evaluation 
Contact the laboratory director to arrange a date for the evaluation. 
• Inform laboratory director of the reason for your visit. 
• Inform the laboratory director that it will be necessary to meet with the 
person(s) responsible for reporting syphilis test results to the STD 
Program. 
• Document the discussion with the laboratory director. 
• Consult with the laboratory evaluation coordinator if request is denied. 
• Review the laboratory’s previous reporting patterns; note the number of 
reactive STS reported during the previous year; and note the mean and 
median number of days between analysis of specimens by the 
laboratory and receipt of the reports by the STD Program. 
2. During the Laboratory Evaluation Visit 
• Meet with the person(s) responsible for reporting syphilis test results to 
the STD Program. 
• Assess and document the laboratory’s reporting procedures. 
• Review the laboratory’s log for the designated time period and 
determine the total number of STS performed and the number of 
reactive tests listed during this period; for a sample of the reactive STS, 
note the date that the specimen was analyzed by the laboratory and the 
date the report was received by the STD Program. 
• Determine the number of reactive STS tests reported during the time 
period of interest and review documentation of reporting, if available. 
3. Following the Laboratory Evaluation 
• Calculate the proportion of reactive STS reported to the STD Program. 
• Calculate the timeliness of reporting. 
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Active Surveillance 
Definition  
Active surveillance involves routine communication with health care providers and 
laboratories to stimulate and maintain case reports. Potential reporters include but are not 
limited to public and private providers, laboratories, managed care organizations, substance 
abuse centers, and corrections facilities. 
Purposes and Uses of Active Surveillance 
Active surveillance at state and local levels can be used for a variety of purposes. In general, 
active surveillance may be used for evaluating the timeliness, completeness, and accuracy of the 
current surveillance system, improving the current system, and evaluating disease control 
initiatives. Specific purposes and uses of active surveillance at state and local levels include the 
following: 
• Evaluate existing surveillance system 
− Permits comparison with existing passive system 
− Determine whether passive reports are representative of disease in 
the community 
• Improve existing surveillance system 
− Improve timeliness of reporting 
− Improve the sensitivity of reporting (health department is receiving 
reports on all cases of disease) 
− Improve the completeness of reporting (disease reports are accurate 
and have complete information) 
− Strengthen case detection efforts (e.g., laboratory and provider 
visitation)  
• Evaluate and improve disease control initiatives 
− Facilitate outbreak detection 
− Quickly and efficiently evaluate disease activity in the community 
by contacting providers and agencies likely to see persons with 
the disease 
− Prompt testing for disease detection 
− Evaluate the effect of disease intervention and prevention activities 
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Box 3. Key Steps in Developing an Active Surveillance System 
1. Develop objectives for active surveillance, and design the system 
accordingly 
• Outbreak detection and response 
• Evaluate current surveillance system  
• Improve completeness of reporting 
2. Develop a list of providers, agencies, and laboratories 
• Make a list of contact persons including telephone and facsimile 
numbers of providers and agencies and laboratories submitting a 
large proportion of disease reports received by the health 
department. 
• Make a list of providers and agencies that would be expected to 
diagnose and treat patients with STDs and a list of laboratories that 
would be expected to perform clinical testing on patients with 
STDs. 
• Make a list of agencies that serve persons at high risk for syphilis 
(e.g., corrections facilities, drug treatment centers, etc.). 
• Develop a strategy to sample providers, agencies, and laboratories 
to determine the timeliness, completeness, and accuracy of 
reporting.  
3. Include contact information on the list of providers and 
laboratories 
• Include telephone numbers, facsimile numbers, e-mail addresses, 
procedures for visiting, etc.  
4. Develop a data collection instrument  
• Determine the information to be obtained when making contact. 
• Create an instrument with the list of questions in order to obtain 
complete and consistent information from each facility contacted. 
• Create a template with questions that pertain to patients with 
genital ulcer disease and syphilis. 
5. Develop a plan for analyzing and interpreting the data 
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 Programs implementing syphilis elimination activities should establish locally defined 
methods for active surveillance. 
It is necessary to establish objectives, methods, and protocols for active surveillance so that 
the activity can be carried out systematically in a variety of sites. The components of and 
structure for active surveillance should be specified to provide state and local project areas with a 
framework for the activity so that specific protocols can be developed. 
State and local health departments should develop active surveillance protocols based on 
the incidence of syphilis in their jurisdiction because the level of morbidity often helps define the 
uses of data derived from active surveillance. For example, in areas with low incidence of 
disease, the primary objective of active surveillance may be to evaluate the sensitivity of the 
surveillance system. In areas of high morbidity that may be experiencing one or more outbreaks, 
active surveillance may be employed continually to ascertain cases from providers on a real time 
basis, independent of the time lag for case verification and reporting. 
State health departments should develop active surveillance protocol templates and should 
provide technical assistance to local jurisdictions in developing local protocols. CDC and the 
National Coalition of STD Directors should collaborate to develop model active surveillance 
protocols. State and local STD staff should consult with general communicable disease 
epidemiology staff when developing active surveillance protocols. 
Health department personnel should increase interaction and communication with 
providers in low-morbidity areas. Close contact with providers in low-morbidity areas is essential 
to ensure that all identified early syphilis cases are reported rapidly and to prevent incipient 
outbreaks of syphilis. 
Active Methods to Ascertain Cases 
Disease control programs have generally relied on provider and laboratory reports for 
ascertaining cases. Intensive disease control activities, such as syphilis elimination, require 
additional methods of case ascertainment. Additional methods that have been utilized by state 
and local programs to ascertain cases include but are not limited to: 
• Targeted screening (e.g., screening at designated sites using mobile units). 
• Outreach efforts (street and otherwise) using community agencies to identify cases. 
• Partner elicitation and notification to learn of potential cases from case-patients. 
• Social network methods or “clustering” (e.g., contacting social contacts for testing 
and treatment services). 
Genital Ulcer Surveillance 
Genital Ulcer Surveillance in STD Clinics 
• STD clinics should keep genital ulcer log books with listings of patients’ names, 
clinical diagnoses given, and laboratory testing if available (an electronic format 
could be used in lieu of a log book). 
• Darkfield microscopy log books should be kept in clinics performing darkfield 
microscopy. 
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• Routine review of these log books would help determine the proportion of STD clinic 
patients with genital ulcers, the proportion of persons with genital ulcers who were 
tested for syphilis and were subsequently found to have syphilis. Analyses also could 
include the proportion of cases with positive darkfield microscopy results and positive 
STS results [non-treponemal and treponemal]. 
The use of a log book allows the area to quantify the number of genital ulcers observed 
over time that are suspicious for syphilis and to quantify the proportion that are positive for T. 
pallidum, or associated with reactive tests for syphilis, and the proportion reported as cases. 
Genital Ulcer Surveillance Sampling and Survey Strategies  
• Health departments should periodically test genital ulcers for etiologic pathogens. 
• Health departments should survey providers regularly to determine the numbers of 
persons diagnosed with genital ulcers in a specified time period and the results of 
diagnostic testing, if available. 
Periodic sampling of genital ulcers in patients in both STD clinic settings and non-STD clinic 
settings enables disease control programs to determine the number of persons diagnosed with 
genital ulcers at facilities and the number of persons with genital ulcers that are positive for T. 
pallidum, HSV, H. ducreyi and other pathogens, and the number of persons with genital ulcers 
who have  reactive serologic tests for syphilis for a specified period of time. Surveys to assess the 
number and etiologic nature of genital ulcer disease should be conducted with providers that 
serve populations at high risk for syphilis. In some circumstances, detailed surveys involving 
medical chart review and abstraction may be appropriate for monitoring the prevalence of 
genital ulcers and clinical management of genital ulcers diagnosed in persons at high risk for 
syphilis.  
• DFA-TP should be utilized whenever available to provide diagnosis of syphilis in 
patients with genital ulcers. 
DFA-TP testing allows specific diagnosis of syphilitic genital ulcers when darkfield is 
unavailable. 
Outbreak Detection 
Appropriate data sources that can be used to detect syphilis outbreaks include 
• case reports (case registry data). 
• laboratory reports. 
• prevalence-monitoring sites. 
Case reports and laboratory reports are good sources of surveillance data for the detection 
of outbreaks. Prevalence monitoring-data may be useful for detecting outbreaks in populations 
regularly screened for syphilis (e.g., arrestees, STD clinic patients, HIV infected patients). For 
conditions of unknown etiology (e.g., genital ulcers of undetermined etiology), clinician reports 
are often the initial indication that an outbreak is occurring.  
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When determining time frames to use for the detection of syphilis outbreaks, the following 
should be considered: 
• Decisions regarding what time frame to use depend on the incidence of syphilis in, 
and the demographic characteristics of, a given area. 
• In areas with substantial morbidity surveillance data should be analyzed at least 
monthly to monitor changes in the incidence of syphilis that may indicate the 
occurrence of an outbreak. Analyses should include demographic data, risk factors 
(e.g., sexual orientation, drug use, sex for drugs or money), geographic information 
(e.g., zip code, census tract) and other characteristics. In addition, analyses should be 
performed to identify increases in overall morbidity or increases in specific 
subgroups. 
• In low morbidity areas, cases should be reviewed as reported and a monthly 
overview should be routinely completed to monitor changes. 
Data must be systematically and routinely reviewed to identify the occurrence of outbreaks. 
Outbreak thresholds must be dependent on area-specific morbidity. For example, an area with 
endemic syphilis may set a threshold above the observed rate, whereas an area with no syphilis 
might set the threshold at a single case. The unit of observation may be defined in a variety of 
ways. One method is to make the unit of observation a defined geographic area and to look for 
an increase above the threshold of cases in that defined area. Another method is to make the 
unit of observation a defined demographic or risk group and to look for an increase above the 
threshold of cases in the defined group. Geographic units of observation are more conventional, 
but, they may not work well to detect outbreaks in such specific subgroups as men who have sex 
with men if they do not live in the same area. A combination of geographic, demographic, and 
risk factor units of observation may be best, especially in areas with substantial morbidity; when 
syphilis is rare and the threshold is low, either strategy may work well. 
Because prompt provider reporting of early syphilis cases is critical to outbreak detection, 
state reporting laws should ensure that reporting syphilis cases is a high priority activity and 
should require that suspected cases of early syphilis are reported immediately to the health 
departments (see case reporting section). 
Electronic Reporting of Laboratory Data 
Case Reporting 
Some of the data elements necessary for reporting syphilis cases and for monitoring 
prevalence are already available in computerized systems maintained by many clinical 
laboratories. Laboratories should be encouraged to report laboratory data electronically to STD 
prevention programs, and STD prevention programs should develop the ability to receive and 
transmit these data. 
When STD prevention programs define variables and develop data formats for case 
reporting and prevalence monitoring, they should provide the data formats to laboratories and 
collaborate with them to ensure reporting. Laboratories should be encouraged to submit 
electronic line-listed data on all persons with reactive STS for case reporting. For prevalence 
monitoring, STD prevention programs should work with laboratories to determine whether line-
listed data for persons with nonreactive STS can also be submitted. 
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Reporting by Out-of-State Laboratories 
Large commercial laboratories often receive specimens from many states. With increasing 
regionalization of commercial laboratories and the centralization of laboratory services within 
managed-care organizations, out-of-jurisdiction testing has become more common. Laboratories 
that perform STS should report reactive STS to the appropriate STD control program for the 
local area or state in which the tested person resides. 
Out-of-State Reporting Algorithm 
The Council of State and Territorial Epidemiologists recommends that the following 
algorithm be used by laboratories when reporting reactive STS to public health authorities in 
multiple jurisdictions (in order of preference): 
a) state where the patient resides; 
b) state where the ordering provider is located (“a” is missing); 
c) state where the original receiving laboratory is located (“a” and “b” are missing); or 
d) state where the laboratory that performed STS is located (“a,” “b,” and “c” missing). 
STD prevention programs should ensure that laboratories within their state are familiar with 
the algorithm.  
Coordination of laboratory-based reporting of reactive STS with reporting of 
other notifiable diseases 
State and local STD-control programs should collaborate with other public health programs 
that are conducting laboratory-based surveillance for other notifiable conditions to minimize the 
duplication of efforts and to efficiently use the laboratory’s reporting resources. 
Many laboratories are required to report data to multiple public health programs within the 
same health department. These public health programs also may request that the data be 
reported in different formats and for different time periods. Collaboration and co-ordination 
within the health department programs that receive data from laboratories will improve the 
efficiency of reporting laboratory-based surveillance data and will simplify reporting procedures 
by laboratories. Because of the large number of laboratories reporting reactive STS, a 
standardized laboratory reporting format should be developed that will accommodate public 
health laboratories at all levels, clinical laboratories, major reference laboratories, and other 
facilities that perform syphilis testing. 
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Prevalence Monitoring 
Priority Populations 
Populations that may be appropriate for routine syphilis screening, and among whom 
prevalence data may be sought, include: 
• arrestees (jails, prisons, juvenile detention centers, at admissions 
• pregnant women (screen during 1st trimester, at approximately 28 weeks gestation, 
and at delivery) 
• STD clinic patients 
• patients with STDs in non-STD settings (private medical providers, urgent care 
facilities, and emergency rooms) 
• clients attending drug treatment facilities (at admission) 
• HIV counseling and testing clients 
• HIV specialty clinic patients (initial and annual visits; more frequently depending on 
local epidemiology) 
• homeless populations 
• family-planning clinic clients 
• community-based site clients (e.g., mobile clinics, bars, bath houses)  
• emergency room patients 
• community health center clients 
Arrestees. Local STD-control programs should establish syphilis screening programs in city 
and county jails. Jail screening programs have demonstrated that there is a high prevalence of 
untreated syphilis in arrestees in numerous jails throughout the United States.7 
Pregnant women. The most efficient prevention method for congenital syphilis is 
screening of pregnant women. Such screening should be conducted at the beginning of prenatal 
care and upon delivery for all women. Testing should be done at or near 28 weeks’ gestation for 
women living in areas with substantial morbidity and for women at high-risk for syphilis. 
Clients attending drug treatment facilities. Areas with substantial morbidity should 
develop screening and prevalence-monitoring projects in facilities specializing in drug treatment.  
HIV counseling and testing clients. Screening for syphilis should be offered regularly to 
clients of HIV counseling and testing sites based on local epidemiology.  
Community-based site clients. Screening for syphilis should be considered in areas with 
high rates of syphilis. Community-based screening may be conducted with the use of mobile 
clinics, at designated sites, or with a “door-to-door” approach. Local epidemiology and 
information from geographic information systems should help guide these activities. 
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Calculation and Definition of Seropositivity and Prevalence 
There are several ways to define prevalence for monitoring disease burden within specific, 
screened populations. What method to use should be based on the analysis being considered 
and on the available data. Prevalence monitoring requires the collection of both negative and 
positive STS results. STD prevention programs should have information systems in place for 
data collection and management, and these systems should facilitate the transmission and 
analysis of data. 
Seropositivity is calculated by dividing the number of reactive STS tests by the number of 
valid STS tests performed during a specified time period. Prevalence is estimated using a single 
test per person during a specified time period. Seropositivity rates may include multiple tests per 
person during a specified time period but may be used to estimate prevalence. Four ways to 
calculate prevalence and seropositivity are listed below, beginning with the most basic and 
proceeding to the most specific approach. Which approach to use should be made on the basis 
of the program’s ability to record and manage these data over time. The use of laboratory 
requisition forms that can be scanned may facilitate prevalence-monitoring activities for large 
screening programs such as those in jails. 
Option 1. Seropositivity (reactive non-treponemal tests) 
Seropositivity should be calculated as the proportion of reactive non-treponemal tests 
among those persons with valid tests in a specified time period. Knowing the seropositivity of 
non-treponemal STS may be used to 1) give crude estimates of the disease burden within the 
screened population; and 2) evaluate the productivity of a given screening site (this may be most 
beneficial in areas with a high incidence of syphilis).  
Option 2. Seropositivity (reactive non-treponemal tests with treponemal test confirmation) 
Seropositivity should be calculated as the proportion of reactive non-treponemal tests with 
reactive treponemal tests (confirmatory) of those persons with valid non-treponemal tests in a 
specified time period. The seropositivity rate of non-treponemal STS with reactive confirmatory 
STS may give a more accurate estimate of the disease burden within the screened population 
than the seropositivity rate of non-treponemal STS alone does and it is useful for determining 
the productivity of screening sites. 
Option 3. Quantitative non-treponemal tests with titers >1:8  
Prevalence should be calculated as the proportion of reactive non-treponemal tests with a 
titer of 1:8 or greater in persons with valid tests in a specified time period. A titer of 1:8 or 
greater has been shown to correlate with infectious syphilis (primary and secondary stages).8 If 
available, treponemal tests should be used to confirm syphilis infection in persons with positive 
non-treponemal tests. 
Option 4. Prevalence of Early Syphilis  
Prevalence should be calculated as the proportion of early syphilis diagnoses (primary, 
secondary and early latent stages) in persons tested the first time in a specified time period. A 
unique patient identifier is required for monitoring early syphilis prevalence. Individuals re-
infected during the specified time period should be counted twice both in the numerator and 
denominator. 
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Provider-Based Prevalence Monitoring 
Because prevalence monitoring may require more resources than case reporting, 
participation by providers should be actively sought by health departments. Participation of all 
providers or all programs is not necessary. State and local STD-control programs should develop 
written criteria for assessing the value of prevalence monitoring and for selecting providers. 
Programs also should seek to obtain access to existing data collected on populations that are 
routinely screened for syphilis. Providers that have one or more of the following characteristics 
should be given the highest priority: 
• those who serve populations at high risk for syphilis (e.g., men who have sex  with 
men, incarcerated persons, person enrolled in drug treatment centers) or who serve 
populations who may be particularly susceptible to the effects of syphilis (e.g., 
pregnant women) 
• those who provide care in areas where there is substantial morbidity  
• those who have sufficient patient volume and consistency  
• those who have electronic information systems that can capture data efficiently 
• those who are capable of screening a representative sample of their clientele 
STD prevention programs should collaborate with providers to develop and maintain 
prevalence-monitoring activities. In developing a collaborative relationship with providers, STD 
prevention programs should: 
• clearly communicate the purposes of prevalence-monitoring activities; 
• consider reimbursement of testing and treatment costs;  
• provide training (with continuing medical education [CME]) and offer technical 
assistance in specific areas of interest (e.g., case management, follow-up procedures, 
diagnostic procedures, treatment, data management, and epidemiology); 
• give providers regular reports of the results of prevalence monitoring, including a 
discussion of their implications for the prevention of syphilis. 
Laboratory-Based Prevalence Monitoring 
Laboratories can be the primary source of prevalence-monitoring data if they routinely 
receive data regarding the sex and age of, and the provider type for persons tested for syphilis. 
State and local STD-control programs should work closely with public health laboratory staff 
members to encourage private laboratories to report these data. The purposes of prevalence 
monitoring must be communicated to the laboratories. In addition, laboratory personnel should 
be informed of state statutes that give health departments the authority to conduct public health 
surveillance (which includes provisions for obtaining both positive and negative test results). The 
relevant statutes and procedures should be provided with written procedures that will assist them 
in ensuring data security and patient confidentiality. To establish and maintain laboratory-based 
prevalence monitoring, health departments should consider the following: 
• Developing a written protocol for laboratory-based surveillance that includes 
discussion of prevalence monitoring. Health department and laboratory 
responsibilities and procedures for prevalence monitoring should be clearly stated. 
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• Maintaining and regularly updating a registry of laboratories that perform STD 
testing (such a registry may be available through CLIA, state, or laboratory 
proficiency providers). 
• Developing protocols that outline procedures for conducting laboratory visits by the 
health department personnel. 
• Providing laboratories with a standardized list of data elements, reporting formats, 
and intervals for reporting syphilis and prevalence-monitoring data. 
• Identifying a health department employee to serve as a liaison to laboratories or to 
serve as the laboratory evaluation coordinator. This person would be the contact 
person for all laboratory surveillance activities. 
• Determining provider types served by each laboratory and the volume and positivity 
rate of syphilis testing completed by each laboratory. 
• Providing regular feedback to laboratories, emphasizing the importance of their data 
to public health prevention efforts. 
• Supporting the development of procedures for  reporting prevalence-monitoring data 
electronically to STD-control programs. 
Reporting Formats and Intervals 
Formats. Whenever possible, prevalence-monitoring data should be collected and reported 
in line-listed format. Line-listed data are preferable to aggregate prevalence data because they 
provide the greatest flexibility for data analysis, data management, and data transfer. 
• Programs that monitor prevalence should adopt standardized, essential data 
elements for line-listed data and ensure that their data systems can export the data in 
a standard format. 
• If aggregate data are collected, they should be reported by sex, site, time period, type 
test, test result, and confirmatory test result. 
Time frames for reporting. Prevalence-monitoring data should be reported quarterly to 
CDC either in line-listed or in aggregate format. 
• STD prevention programs and other prevalence-monitoring programs should 
provide data within 90 days after the end of each quarter. Programs are also 
encouraged to send updated, end-of-year data to allow the data set to be closed out 
each year. 
• If line-listed data are provided, a mechanism should be established to enable 
amendment, correction, and updating of records previously submitted within the 
year of report. 
• Local and state public health programs that monitor syphilis prevalence should have 
the flexibility to establish daily, weekly, monthly, or quarterly reporting time frames 
according to the needs of individual programs. 
Data Elements for Prevalence Monitoring 
Many of the data elements that should be collected for purposes of syphilis prevalence 
monitoring are identical to those being collected for the purposes of case reporting. 
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The compatibility between case-reporting and prevalence-monitoring data systems at state 
and local levels should facilitate collection, transmission, and analysis of data. 
The development of a standard list of core data elements (an abbreviated list of required 
data elements) that can be transmitted in a uniform format is necessary for comparing data 
collected by different screening sites, project areas, and regions throughout the United States. 
Standard data elements would facilitate the collection and transmission of data. Additional 
variables could be collected and used by health departments to evaluate screening programs, to 
manage resources, to generate research questions, and to plan intervention activities (Appendix 
2).  
Behavioral and Social Surveillance 
Behavioral and social data can complement case-reporting and prevalence-monitoring data 
by tracking and anticipating changes in the epidemiology of disease and by identifying risk 
factors associated with infection.9 Prompt and accurate behavioral and social data are necessary 
to maintain effective prevention and intervention programs.10 Questionnaire-based behavioral 
data to inform prevention can be collected in a number of ways including general population 
surveys, behavioral surveillance of populations at risk for, or infected with, syphilis, and as part 
of specific intervention studies. 
Purposes and Uses of Behavioral and Social Surveillance 
• To monitor and track the risk behaviors and social factors that contribute to disease 
acquisition and transmission 
• To identify populations that are at risk for acquiring STDs 
• To help identify behaviors and social factors that can lead to the prevention of STDs 
The development of effective behavioral interventions aimed at syphilis control and 
elimination must be guided by behavioral, social, and contextual data from infected populations, 
at-risk populations, and from communities with high rates of syphilis.  
Existing and Potential Data Sources 
Behavioral and social surveillance data are generally collected at three levels: the general 
population, an infected population, and a population at high risk for infection. General 
population surveys have been used to monitor change in risk exposures in the general 
population over time. Such surveys are limited in their ability to monitor changes in uncommon 
behaviors (e.g., risky sexual behaviors), and in their ability to monitor risk exposure in infected, 
at-risk populations or affected communities. Behavioral surveillance of infected populations and 
of populations at risk is critical for monitoring and controlling the spread of disease. 
Existing Behavioral Surveillance Data Sources 
1. General Population Surveys 
− National Health Interview Survey (NHIS) 
− Behavioral Risk Factor Surveillance System (BRFSS) 
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− Youth Risk Behavior Survey (YRBS) 
− National Household Survey on Drug Abuse (NHSDA) 
−  National Survey of Family Growth (NSFG) 
− National Health and Nutrition Examination Survey (NHANES) 
− General Social Survey (GSS) 
2. Infected Populations 
− HIV/AIDS Reporting System (HARS) 
− Sexually Transmitted Disease Management Information System 
(STD-MIS) 
− Supplement to HIV/AIDS Surveillance (SHAS) 
− Locally developed information management systems 
− Gonococcal Isolate Surveillance Project (GISP) 
3. Surveys of Populations at High Risk for Infection 
− Arrestee Drug Abuse Monitoring HIV addendum (ADAM) 
− HIV Testing Survey (HITS) 
− Drug Abuse Warning Network (DAWN) 
Potential Data Sources 
Successful control of the transmission of syphilis depends on the ability to identify 
populations at risk for infection and to identify behaviors associated with syphilis. Behavioral 
surveillance is required for both of these activities. Behavioral surveys of infected persons and of 
groups at risk for infection have been conducted primarily to help design and evaluate specific 
interventions rather than to monitor trends over time. Surveys of persons at risk for syphilis and 
of persons infected with syphilis are necessary to describe risk exposures and to develop 
appropriate intervention strategies. Methods that state and local programs could use to obtain 
this information include the following: 
• Routinely administered supplemental items to the syphilis interview record collecting 
behavioral information 
• Routinely or periodically administered surveys of at risk persons (e.g., sexually 
transmitted disease clinic patients, incarcerated populations, sex workers, men who 
have sex with men) 
• Cross sectional interviewer-assisted street-intercept surveys conducted in areas of 
high morbidity, repeated periodically 
Data Elements 
Selection of behavioral and social data elements can be guided by the three determinants of 
transmission:11 
• Exposure to infection 
− Number of sex partners 
− Prevalence in sex partners 
− Location of sex partner recruitment 
− Sexual mixing patterns  
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− Exchange of sex for money or drugs 
− Drug use by individual or sex partner 
− History of STDs or incarceration  
− Recent partners 
− Gender of partners 
− Concurrent partners 
− Frequency of intercourse 
• Efficiency of transmission 
− Sexual practices  
− Condom use  
Duration of infection 
Access to treatment 
Interval between onset of symptoms and treatment 
− Perceptions about service providers 
− Self treatment 
− Symptom awareness 
Data Collection Methods 
Collection of behavioral information is based on self-report most of the time. Potential 
biases inherent in self-reported information include recall bias and information bias. In some 
instances recall bias can be minimized by careful wording of survey questions. The “critical 
event” approach asks respondents to recall behavior only for the last time the event occurred 
(e.g., the last time you had sex, did you or your partner use a condom?).12 This method has 
been used to minimize recall bias. Bias caused by a respondent’s desire to give “correct”or 
socially acceptable responses may be minimized by: 
• Considering population characteristics when selecting data collection methods 
− Language spoken or facility with English 
− Literacy 
− Comfort level 
− Facility (public vs. private) 
− Cultural characteristics 
• Establishing quality control for information-collection efforts 
− Instrument development 
− Interviewer training and supervision 
• Considering alternative methods of information collection to enhance validity and 
reliability of data and to gain access to populations that are generally difficult to 
reach 
− Computer-assisted methods 
− Web-based surveys 
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Analysis and Interpretation of Behavioral and Social Data 
• Develop a common set of standard data elements for all data collection systems to 
enhance comparability of data 
• In areas of high morbidity, behavioral data should be monitored regularly to assess 
changes in risk behavior over time 
Community Involvement with Data Collection, Analysis and Interpretation 
• Health departments should develop structured communications with: 
− Community representatives 
− HIV community planning groups 
− Advisory boards 
− Academia 
− Other health department agencies  
Data Quality 
Data Quality for Case Reporting 
Incomplete reporting of data elements and reporting delays can adversely affect data 
quality. All programs should have written quality assurance plans that specify quality control 
procedures for data collection. Data quality-assurance activities should be documented, and the 
results of these activities should be monitored. Specific surveillance indicators should be 
established and monitored regularly at defined intervals. Reports on data quality should be 
distributed to providers and laboratories on a quarterly basis in an effort to provide feedback on 
reporting performance. 
Examples of indicators include the following items: 
• proportion of specific variables for which data is complete; 
• time between the date of the index diagnostic test and other significant events in the 
investigation; 
• laboratory and provider reporting time frames (time from diagnosis or laboratory 
analysis to when the health department received the report); 
• data comparisons between surveillance systems, and; 
• validity of data (e.g., no pregnant males, valid dates). 
Transmitted data should be reviewed to identify duplications, errors, and omissions on a 
quarterly basis at local, state, and national levels. Data transmitted to CDC should be reviewed 
for accuracy, completeness, sensitivity, promptness, validity, and quality on an annual basis.  
Quality-control procedures should be used to provide routine, continuing assessments of the 
accuracy of demographic data (e.g., the patient’s age, race and ethnicity, and geographic 
location). The following quality-control measures should be considered by local and state 
programs:  
• Design data-entry systems with built-in error checks. 
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• Use logic checks and restricted data-entry protocols because of the large volume of 
collected and transmitted syphilis cases reports. For example, such procedures could 
ensure that logical dates are recorded (e.g., the date of specimen collection must be 
before the date of report to the health department).  
• Generate frequency distributions of selected data elements to evaluate data validity. 
The selected data elements should allow direct comparison with other appropriate 
data distributions and should not be open to variable interpretation. For example, a 
clinic’s review of its population’s age or race distributions may identify 
inconsistencies when compared to the expected distribution. In addition, test type 
should match the actual test type being used.  
• Trends in positivity rates by risk factor should be evaluated regularly to assess data 
validity. Once disease trends are established, any unexpected changes should be 
investigated. 
State and local STD prevention programs should submit updated or corrected case-report 
data to CDC as soon as possible. 
Data Quality for Prevalence Monitoring 
Prevalence monitoring programs should have written protocols that specify quality control 
procedures for data collection. Data quality assurance activities should be documented, and the 
results of these activities should be monitored. Specific surveillance indicators (e.g., the 
proportion of data fields that are completed and reporting lag time) should be established and 
monitored at regular, defined intervals. Periodically, data-quality reports should be distributed to 
providers and laboratories to provide feedback on data quality. STD prevention programs 
should monitor the completeness, validity and timeliness of prevalence data. 
Completeness refers to the proportion of data fields with complete information. The 
following recommendations should be considered with respect to completeness of prevalence 
data and methods for assessing completeness of these data. 
Routine Analyses for Assessing Completeness of Prevalence Data 
• Examine proportion of fields completed 
• Examine proportion of test results that were unsatisfactory  
• Examine and monitor the proportion of eligible individuals actually screened. This 
analysis provides one indication of the representativeness of the population being 
monitored (i.e., the higher the proportion the more representative of the population). 
• Examine screening protocols to eliminate or identify sources of systematic bias (e.g., 
not screening on weekends) 
Criteria for Assessing Completeness of Prevalence Data 
• Sex should be 100% complete 
• Age, race, ethnicity, and geographic location (e.g., county and zip code) should be > 
90% complete 
• Type of clinic to which the patient presented (e.g., family planning or STD) should 
be 100% complete 
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• Programs should compare the volume of reported data to actual screening activity 
using laboratory or clinic sources (e.g., records and logs) 
Validity refers to the accuracy of the information contained in each data element. The 
validity of STD surveillance has two components. The first is the extent to which the data in the 
prevalence monitoring record correctly reflects what exists in the primary data source (e.g., 
medical record or laboratory report). The second is the extent to which the primary data source 
is accurate. The following recommendations regarding validity should be considered for 
prevalence monitoring data. 
• Data entry systems should have built-in error checks 
• Frequency distributions should be examined to identify gross irregularities of data 
• Quality-control procedures should be used to provide routine, on-going assessments 
of the accuracy of basic demographic data 
Timeliness refers to the time intervals between steps in surveillance, expressed as a mean or 
median number of days or as a proportion that is greater or less than a defined interval. The 
following recommendations regarding timeliness should be considered by programs conducting 
prevalence monitoring activities. 
• Prevalence monitoring sites should submit corrected data (line-listed and aggregate) 
at least quarterly to the state or local programs involved with these activities and 
within 90 days of the end of the quarter 
• Prevalence monitoring sites submitting data to state or local programs or sites 
submitting data to CDC should submit corrected end-of-year data within 90 days of 
each calendar-year 
Data Analysis and Interpretation 
Case-Reporting Data 
Analysis and interpretation of data and dissemination of the resulting information are 
necessary to complete the process of case reporting. The analyses recommended here are 
intended to address the overall purposes of syphilis surveillance discussed previously. 
Every local, state, and national program should perform a comprehensive analysis of its 
case-reporting data annually. In addition, abbreviated analyses should be performed more 
frequently. Abbreviated analyses should be performed monthly in areas with substantial 
morbidity and in low morbidity areas, cases should be reviewed as reported. 
Types of Analyses 
Analyses that are performed more frequently than annually should include an examination 
of quarterly or monthly trends in the number of reported early syphilis cases for the preceding two 
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years. These analyses should be presented for all reported cases and may be stratified by the 
following categories depending on local epidemiology:  
− geographic area (e.g., census tract, zip code, county, state) 
− sex 
− age group 
− race/ethnicity 
− provider type 
− provider site 
− reporting laboratory 
− test type 
− disease stage 
− anatomic site of primary lesions 
− sexual behavior (e.g., gender of sex partners, exchange of sex for 
money) 
On an annual basis, every local area and state should analyze all early syphilis cases 
reported during the year and all cases stratified by the categories listed above. In addition, as 
part of the analysis, local areas, states, and CDC should determine the annual rates in syphilis 
using the most recent census data available or intercensal estimate. Calculated rates represent 
the minimum incidence of early syphilis. These rates should be compared with the rates for 
previous years for all cases and stratified by the categories listed above. 
Stratification by sex, age group, and race and ethnicity is important in the analyses because 
it allows specific detection of disease activity in groups of people that may be particularly 
susceptible to or at increased risk for infection. Stratified analyses are recommended when 
populations are large and when disease rates are high or increasing. 
Other important analyses that should be performed annually: 
• Examination of the syphilis and HIV co-infection rates 
• Comparison of the rates and trends of syphilis obtained from case reports and from 
prevalence monitoring 
The following factors should be considered when analyzing and interpreting data from 
syphilis case reports and prevalence monitoring: 
• Changes in case reports or prevalence may be real or the result of changes in 
screening, reporting practices, or test type. Any marked change in reported cases or 
prevalence should be investigated to determine the probable cause. 
• Case-reporting data can be used reliably to monitor trends in disease burden when 
the screening activities are not changing, when access to and use of clinical services 
are stable, and when diagnostic and reporting practices are consistent over time. 
During periods when program activities increase, increases in reported cases may 
reflect elevated rates of screening. A decline in the number of reported cases may be 
the result of reduced screening activities or a decline in reporting by providers or 
laboratories. 
• The identification and use of correct population totals are crucial for comparing 
disease burden among groups. Census data stratified by geographic location, sex, 
age group, and race/ethnicity must be used for calculation of population-based rates 
of case reports for each of these categories. 
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• Low case-reporting rates in areas with a high prevalence of disease may indicate that 
rates of screening are low or that cases are being under-reported. 
• Analyses of rates of syphilis and HIV co-infection at local, state, and national levels 
can help elucidate relationships between these diseases in different areas and 
nationally. 
• Determining the number of case reports submitted by major providers and large 
laboratories can help to identify sites that have recent increases or decreases in levels 
of testing and reporting. Providers and laboratories with recent increases or 
decreases in reported cases should be contacted to determine whether an outbreak is 
occurring or whether there has been an interruption in screening for syphilis or 
reporting cases. 
• Determining the number of imported cases reported, the demographic 
characteristics, and risk factors of imported cases that cross jurisdictional borders is 
important. 
Prevalence-Monitoring Data 
Analysis and interpretation of data are necessary to complete the process of prevalence 
monitoring. State and local STD-control programs should perform the following analyses, 
quarterly and annually, of syphilis prevalence data to monitor disease burden and trends. 
Examine syphilis prevalence (seropositivity, confirmed seropositivity, high-titer 
seropositivity, and actual prevalence of untreated disease) by the following: 
• prevalence monitoring site 
• site type 
• sex 
• age group 
• race and ethnicity 
• year 
• zip code or census tract 
• behavioral risk factors 
• disease status or stage 
Analyses of changes in the prevalence of syphilis in screened population are important for 
identifying and describing trends. 
• Laboratory prevalence monitoring sites should analyze syphilis prevalence by 
provider type (e.g., family planning physician, jail). 
• Prevalence of syphilis during the current year should be compared with prevalence 
during previous years and stratified by the categories listed above. 
• Rates of co-infection of syphilis with other STDs (e.g., HIV, gonorrhea, chlamydia) 
should be determined regularly. 
Assessment of Screening Coverage 
State and local STD-control programs should collaborate with participating clinics to 
evaluate syphilis screening procedures and rates. Local and state STD prevention programs 
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should periodically assess syphilis screening coverage in their jurisdictions, particularly in settings 
that serve populations at increased risk for syphilis (e.g., clinics that provide care for HIV-
infected persons, men who have sex with men, drug treatment facilities, correctional facilities, 
and emergency rooms). 
Dissemination and Communication of Findings 
Case-Reporting Data 
A plan for regular dissemination of information derived from the analysis of syphilis cases 
should be developed at local, state, and national levels. Special consideration should be given to 
providing data to local STD-prevention programs, reporting laboratories, or other agencies that 
significantly contribute to the collection of the data. Findings based on information obtained 
from syphilis case reports should be summarized in newsletters, presentations, e-mail 
correspondence, website presentations, or formal reports on a quarterly basis. Formal reports 
should be prepared annually. In areas where syphilis occurs rarely, information may be 
disseminated less frequently than in areas with high rates of disease, but reports should be 
prepared at a minimum on an annual basis. 
Prevalence-Monitoring Data 
STD control programs should tailor the dissemination and communication of STD 
prevalence monitoring data to specific audiences. Public relations personnel or Public Health 
Information Officers should be consulted when practical. These reports should include a concise 
interpretation of the data. Quarterly reports of prevalence monitoring activities should be 
prepared for the following: 
• sites involved with monitoring activities (e.g., jails, drug treatment centers); 
• health departments; 
• laboratories; 
• syphilis advisory groups; 
• professional medical groups. 
Annual reports of prevalence monitoring activities should be prepared for: 
• community-based organizations; 
• organizations representing populations at risk for syphilis; 
• general public through mass media; 
• HIV programs and community planning groups; 
• legislators and policy makers; 
• faith communities; 
• public and private health care providers; 
• local and state public health agencies. 
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Information Systems  
Information System Design 
Effective information systems allow public health agencies to 1) monitor disease trends; 2) 
collect data to improve decision making; 3) collect and use data for solving health problems and 
for planning interventions; and 4) ensure the effectiveness, accessibility, and quality of personal 
and population-based health services. The CDC is collaborating with state and local health 
departments in implementing the National Electronic Disease Surveillance System (NEDSS) to 
better manage and enhance the large number of current surveillance systems and allow the 
public health community to respond more quickly to public health threats.13 When completed, 
NEDSS will electronically integrate and link together several types of surveillance systems with 
the use of standard data formats; a communications infrastructure built on principles of public 
health informatics; and agreements on data access, sharing, and confidentiality. Specific 
recommendations for designing information systems include the following: 
• Information systems must have the flexibility to accommodate new data elements 
and new technologies. 
• Information systems should facilitate the analysis of electronic data at local and state 
levels.  
• Systems should include a unique patient identifier to link multiple serologic tests for 
syphilis, syphilis case reports, and for other notifiable STD and communicable 
disease reports (i.e., systems should be patient-based not event-based).  
• Systems should allow the transmission of provisional data that can be updated at a 
later time to improve the timeliness of syphilis surveillance. 
• Local and state programs should be fully capable of collecting, storing, and 
transmitting required data elements. 
• Systems should allow additional data not included in required data elements to be 
collected at local and state levels. 
• New information systems must be capable of accommodating all variables from the 
old information systems. 
• Adequate technical support is necessary to operate and maintain systems. 
• Information systems must be capable of transmitting syphilis case data in a line-listed 
fashion using an extended record format. 
• Once information used by STD-control programs is entered electronically, efforts 
should be made to maintain the data electronically, eliminating duplicate data entry 
efforts at various points within the system. 
• CDC and local and state programs should describe risk behaviors of people with 
syphilis.  
• Information systems should allow case-reporting data to be linked to the data 
collected and used for case management and partner follow-up. 
• Information systems should facilitate the production of standardized reports 
summarizing data from case reports, and these reports should be accessible to 
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health-care providers and laboratories, STD program managers, health department 
policymakers, and others in the medical and general community. 
• STD information systems should be capable of linking with other data systems 
including ones developed to collect, store and transmit data about immunizations, 
tuberculosis and HIV/AIDS. Public health departments should establish a working 
group, comprised of information systems experts, program managers, 
epidemiologists, and other stakeholders, to plan a unified information system 
structure across public health disciplines. 
• Information systems at state and local STD prevention programs should be capable 
of receiving syphilis data electronically from laboratories. Information systems should 
enable the collection, storage, and transmission of data from persons with reactive 
STS and nonreactive STS, so that syphilis seroprevalence can be monitored in clinics 
and other defined populations. 
Although laboratory protocols for electronic reporting are being developed, certain data 
elements essential for surveillance are not routinely available from laboratory information 
systems. Until other sources of data can be electronically linked to laboratory information 
systems (e.g., provider information systems, pharmacy information systems, hospital information 
systems, insurance and health plan information systems, and vital records), linking provider case 
reports with health department follow-up information will be necessary to obtain complete 
information on syphilis cases. 
Privacy and Data Security 
The Health Insurance Portability and Accountability Act of 1996 (HIPAA) mandates that the 
United States adopt national uniform standards for electronic transactions related to health 
insurance enrollment and eligibility, health-care encounters, and health insurance claims; for 
identifiers for systems used in these transactions; and for security of these transactions.14 The 
exchange of health data must include provisions for the protection of patient privacy. STD 
control programs must develop and maintain comprehensive data-security policies to ensure the 
following:  
• the confidentiality of disease-control data and the privacy of individuals (prevention 
of unauthorized disclosure of information); 
• the integrity of disease-control data (prevention of unauthorized modification of 
information);  
• the availability of disease-control data for authorized persons (prevention of 
unauthorized or unintended withholding of information or resources); and  
• appropriate use of surveillance data solely for public health purposes.  
Maintaining the privacy of the collected information is necessary because significant 
personal, psychological, and economic damage may occur if information about the personal 
health and behavior of individuals is disclosed. Most states have statutes and laws protecting the 
confidentiality of public health data maintained by governmental agencies. Policies concerning 
data security must be developed in compliance with state and local statutes protecting the 
privacy of individuals and the confidentiality of public health information.  
Some state and local statutes limit reporting requirements to persons who test positive for 
notifiable diseases. The legality of reporting data for persons with negative tests should be 
addressed. Guidelines should be developed which clarify procedures for the transmission of line-
listed data with or without personal identifiers to help protect the confidentiality of reported data. 
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Training and Personnel 
Innovative approaches for training and career development of STD surveillance personnel 
should be developed and supported at the national level and local levels. Some approaches may 
include: 
• providing training for health department personnel in a variety of program areas 
(e.g., STD, HIV, or communicable diseases) and public health disciplines (e.g., 
epidemiology, biostatistics, and program management), to improve the capacity of 
existing personnel to conduct effective surveillance; 
• using a variety of training approaches (e.g., rotation of staff through “model 
programs,” distance learning, train-the-trainer programs, teleconferencing, data 
analysis workshops); and 
• encouraging NCSD and CSTE to work with CDC to help provide technical 
assistance to STD prevention programs that have a limited capacity to conduct 
syphilis surveillance. 
Analysis, interpretation, and dissemination of surveillance data are essential for effective 
surveillance systems and they allow health departments to make informed decisions and to 
apply evidence-based information in their efforts to design and implement prevention and 
intervention strategies. 
Case-reporting and prevalence-monitoring activities require a variety of skills. Local, state, 
and federal public health agencies should cooperate to develop approaches for training and 
career development of STD surveillance personnel. Skills and areas that training should address 
include: 
• epidemiology; 
• data management; 
• information systems; 
• data entry; 
• basic disease knowledge; 
• STD surveillance; 
• outbreak detection and response. 
In addition to case reporting and prevalence monitoring, there are specific personnel and 
training needs for active surveillance and outbreak detection: 
• each project area should collaborate with an epidemiologist;  
• state and local health departments should obtain funding to support an 
epidemiologist position for STDs even if not full time; 
• each project area should have an STD information management specialist; 
• each project area should have an STD surveillance coordinator; 
• each project area should communicate with their state epidemiologist to assure that 
the state epidemiologist is familiar with state STD epidemiologic data.  
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Epidemiologic expertise is necessary to help ensure that syphilis surveillance data are 
collected systematically, data are analyzed and interpreted appropriately, and that surveillance 
findings are disseminated effectively to promote the elimination of syphilis transmission. 
Data management and coordination are necessary for the systematic collection of 
surveillance data, appropriate analysis, and interpretation of data, and effective dissemination of 
surveillance findings to promote the elimination of syphilis transmission. 
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APPENDIX 1 
 
Sample Serology Laboratory Site Visit Report 
 
Region  ____________    Worker  _________________ Date of Visit       ____/____/____ 
 




Type of Laboratory   [ ] Hosp  [ ] PMD  [ ] Clinic    [ ] Public      [ ] Private 
 
Type of Testing  
Nontreponemal  [ ] RPR  [ ] VDRL   [ ] Other _____________ 
Treponemal  [ ] TPPA  [ ]FTA-ABS [ ] EIA [ ] Other _____________ 
 
Person or Unit Responsible for Reporting __________________________________ 
 




Format of Report (Attach sample)   [ ] Lab slip [ ] Report form [ ] Electronic 
 
How often are reports submitted to the Health Department? ______________________________ 
 





Components of the Report (match to state requirements) 
[ ] Type of specimen  [ ] Name of patient  [ ] Patient DOB 
[ ] Specific test   [ ] Age of patient   [ ] Address of patient 
[ ] Date test performed  [ ] Physician/Agency name  [ ] Medical record number 
[ ] Result    [ ] Physician/Agency address 
 
Time Period for the Evaluation 
  Begin date: ____/____/____   End date ____/____/____ 
 
How many serologies were done in this laboratory during the time period?  ____________ 
 
How many reactive serologies were there during the time period?     ____________ 
 
How many reactive serologies were reported to the Health Department?    ____________ 
 
Proportion of reactive serologies reported to the health department ____________%   (See Worksheet if needed.) 
 
Mean and median reporting time for the laboratory reporting (days).   (See Worksheet if needed.) 
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Sample Serology Laboratory Site Visit Report 
Worksheet  
 
Completeness of Reporting 
 
All laboratories are required to submit reports of reactive serology to state or local health departments.  The program 
should decide in advance the minimum percentage of reported reactive serologies that is acceptable.  100% of reactive 
tests should be reported to the health department, but the actual percentage required is a local area decision. 
 
A. How many reactive serologies were documented at this laboratory during the time period?_________ 
 
B. How many reactive serologies were reported to the health department from this laboratory during the time 
period?________ 
 
C. Divide B by A = ____________________= Proportion of reactive serologies reported by the laboratory to the 
STD program or Completeness of reporting. 
 
 
Completeness of Information 
 
Completeness of information assesses the degree to which laboratories are providing complete information in their reports. 
 For example, a laboratory may report 100% of its tests but provide patient names for only 60%, clinician names for only 
70%, and serology titers for only 90%.  The following steps will provide an indicator of completeness of information. 
 
A. How many data fields are required to be reported for each lab report (e.g., patient name, address, age, date of 
birth, race, sex, test type, test date, test result, submitting clinic/clinician name and telephone number, etc.)? 
 
B. In separate categories, record the number of laboratory reports with complete information, and the number 
missing one, two, three, four, or more data fields. 
 
C. Divide each of the numbers in B by the number of laboratory reports reviewed to obtain the percentage of 




State statutes regulate the time period within which reports of reactive serologies must be submitted to the health 
department.  This time period is the time from when the laboratory analyzes the specimen to the time that the health 
department receives notification of a positive serology. 
 
A. Pull a sample of reactive serologies received by the STD program from the laboratory and for the time period 
under evaluation. 
 
B. For each serology reviewed record: 
 
date serology   date report received      days btwn serology   
analyzed by lab.   by health dept.    & report received 
__/__/__    __/__/__     _______ 
 
C.     Calculating the mean reporting time for the laboratories is one measure of the timeliness of reporting.  However, 
a more useful measure is the median reporting time which is less vulnerable to outliers.   
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Example: Annual Clinical Laboratory Survey Calendar Year  
(Use space below to record laboratory name and address) 
_____________________________________ 
     
_____________________________________ 
 
CLIA Number: ___________________ 
 
Laboratory Director: _______________________________     Phone: ________________________ 
 
Professional Degree(s): ______________________________________________________________ 
 
Contact Person: __________________________________  Title: _____________________ 
 
Phone: __________________________________________ FAX: _____________________ 
 
 
1. Which of the following categories best describes your laboratory? (Check one.) 
 
___ Private Hospital   ___ Free-Standing Private  
___ Public Health     ___ Non-Profit Hospital 
___ Blood Bank   ___ Custody Facility 
___ VA/Military Hospital  ___ Community Clinic  
___ Student Health Services     ___ Physicians Office/Group Practice   
___ HMO    ___ Other (specify) _______________________ 
 
2. If no STD (syphilis, chlamydia, gonorrhea, chancroid, herpes, HIV, etc.) or TB tests were performed on site, please 
check the appropriate line below and return the survey in the envelope provided.   
 
___ No STD or TB tests were processed through or performed by this facility this year. 
___ This facility is a Draw Station for: ____________________________________________ 
 
3. Are any STD specimens sent to laboratories outside the state or county for testing?____ Yes   ____ No 
 
  If AYes,@ please indicate the approximate percentage _________ and laboratories used: 
 
  Lab Name ___________________________ CLIA # ________________ State _______ 
 
  Lab Name ___________________________ CLIA # ________________ State _______ 
 
4. Are any STD specimens for testing received from clinical providers located outside the state or county?  
 
___ Yes ___ No  If AYes,@ indicate the approximate percentage (check one). 
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Indicate by circling ANo@ or AYes@ those tests currently performed by your laboratory.   Record the number of tests and the 
number positive for CALENDAR YEAR ----.  Please be as precise as possible. 
 
                    
  
5. SYPHILIS:  Performed? # Performed # Positive Number of Days* 
 
RPR (Qualitative) No  Yes  ____________ ____________     ____________     
RPR (Quantitative) No  Yes  ____________ ____________     ____________ 
VDRL (Qualitative)  No  Yes  ____________ ____________     ____________      
VDRL (Quantitative    No  Yes  ____________ ____________     ____________      
FTA-ABS       No  Yes  ____________ ____________     ____________      
TPPA         No  Yes  ____________ ____________     ____________      
VDRL on CSF  No  Yes  ____________ ____________     ____________      
Darkfield         No  Yes  ____________ ____________     ____________      
DFA-TP         No  Yes  ____________ ____________     ____________ 
EIA   No  Yes  ____________ ____________     ____________      
Other:___________    No  Yes  ____________ ____________     ____________      
                        ___________    No  Yes  ____________       ____________     ____________      
     
 * Please indicate the number of days per week test is performed.  
 
Are Arough@ non-treponemal tests diluted to rule out prozone reactions?   ____ Yes  ____ No 
 
What is policy for performing confirmatory (treponemal) tests: 
 
____  Routinely, on all reactive non-treponemal findings 
 
____  By Request Only         
                     
           
  
               
6. GONORRHEA:   Performed? # Performed # Positive Manufacturer                        
                                                               
 
Urethral Gram Stain* No  Yes   ____________    ____________    _____________________    
GC Culture  No  Yes       ____________    ____________    _____________________ 
Gen-Probe PACE 2    No  Yes        ____________    ____________    _____________________ 
Digene Hybrid Capture 2  No  Yes         ____________    ____________    _____________________ 
LCR         No  Yes         ____________    ____________    _____________________ 
PCR   No  Yes   ____________    ____________    _____________________ 
TMA   No  Yes   ____________    ____________    _____________________ 
SDA   No  Yes   ____________    ____________    _____________________ 
  Other: ___________    No  Yes         ____________    ____________    _____________________ 
 
      * Please do not include gram stains done to identify culture isolates 
 
 
Does the laboratory perform MICs on positive gonorrhea cultures?  ____ Yes  ____ No 
 







   
                       
46 Recommendations for Public Health Surveillance of Syphilis in the United States 
7. CHLAMYDIA:  Performed? # Performed # Positive Manufacturer 
 
Culture   No  Yes  ____________    ____________ _____________________ 
DFA        No  Yes  ____________    ____________ _____________________  
EIA        No  Yes  ____________    ____________ _____________________      
Gen-Probe PACE 2        No  Yes  ____________    ____________ _____________________  
      Digene Hybrid Capture 2 No  Yes  ____________    ____________ _____________________ 
LCR        No  Yes  ____________    ____________           _____________________      
PCR        No  Yes  ____________    ____________ _____________________ 
TMA        No  Yes  ____________    ____________ _____________________ 
SDA                 No  Yes  ____________    ____________  _____________________ 




Is a confirmatory assay routinely performed on positive EIA findings?   ____ Yes  ____ No 
 
Is a confirmatory assay routinely performed on positive DNA probe findings?     ____ Yes  ____ No 
 
Are specimens giving positive DNA probe findings in a Agray zone@ retested?  ____ Yes  ____ No 
 
      If yes, please describe your negative gray zone cut-off, type of test, and dates.        
______________________________________________________________________ 
 
Does laboratory perform C. trachomatis serologic testing?  ____ Yes  ____ No 
 
 
8. HEPATITIS B: 
 
Hep. B Surface Antigen  ____No ____Yes   # performed ______   # positive ____    
          
Test Manufacturer _________________ 
 
 
9. HIV:   Performed? # Performed # Positive Manufacturer 
 
EIA   No  Yes  ____________     ____________   _______________________  
Western Blot  No  Yes       ____________     ____________   _______________________ 
IFA   No  Yes       ____________     ____________   _______________________ 
PCR   No  Yes                ____________     ____________    _______________________  
Other: ______________         Yes   ____________     ____________   _______________________     
 
    
10. HERPES SIMPLEX VIRUS (HSV): 
 
Performed? # Performed # Positive Manufacturer 
 
   Culture  No  Yes       ____________     ____________    _______________________ 
   DFA   No  Yes       ____________     ____________    _______________________  
   Other: _____________             Yes       ____________     ____________    _______________________      
 
 
11. HUMAN PAPILLOMA VIRUS INFECTION (HPV): 
 
Performed? # Performed # Positive Manufacturer 
Test Type ___________ No Yes       ____________     ____________    ______________________      
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12. CHANCROID (Haemophilus ducreyi): 
 
Performed?  # Performed  # Positive 
 
     Gram Stain        No  Yes  ____________     ____________         
   Culture        No  Yes       ____________     ____________         
 
    
13. TUBERCULOSIS (TB): 
Performed?  # Performed  # Positive 
 
     Culture        No  Yes       ____________     ____________      
   Smear         No  Yes       ____________     ____________      
     
 
 
14. Does this laboratory use a reference lab to confirm any positive STD tests?   _____ Yes _____ No 
 
   If AYes,@ please indicate for which tests and the laboratories used.  
 
    Test   Laboratory   City 
 
_______________  ____________________       ______________________________ 
 
_______________  ____________________       ______________________________ 
 
_______________  ____________________         ______________________________ 
 
 
15. Does your laboratory have a computerized data system?    ____ Yes ____ No 
 
   If  AYes,@ please answer the following questions: 
 
Is it a commercially available software program?   ____ Yes ____ No 
 
If  AYes,@ specify ________________________________________________________    
 
Information Collected:   _______ Billing   ______ Provider   ______ Patient   _____ Test Results 
 
Is lab able to generate periodic reports of negative and positive results for individual providers? 
 ____ Yes  ____ No 
 
 
16. How does your laboratory report test results?   
 
By mail _____   By FAX ____   Electronically ____    Other ________ 
 
 
17. How often does your laboratory report? 
 
       Daily ____    Weekly ____    Monthly ____ 
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APPENDIX 2 
Table 1. Minimum data elements for syphilis prevalence monitoring 
 
Variable Standardization 
Date of birth (or age) MM/DD/YYYY (or age at date of specimen collection) 
Sex Male, Female 
Race American Indian/Alaskan Native, Asian, Black or African-American, Native 
Hawaiian or other Pacific Islander, White, Other, Unknown 
Ethnicity Hispanic or Latino, Not Hispanic or Latino, 7=Other, 8=Unknown 
County of patient residence (or other 
appropriate geographic locator including city, 
zip code or census tract)  
3-Digit FIPS code 
Date of specimen collection MM/DD/YYYY 
Site Identifier Jail, Family planning, Prenatal, STD clinic 
Laboratory test type Type of laboratory test (e.g., RPR, VDRL, FTA) 
Qualitative laboratory test result Qualitative result of laboratory test (i.e., non-reactive, reactive, 
unsatisfactory, missing) 




Table 2. Enhanced data elements for syphilis prevalence monitoring 
 
Variable Standardization 
Unique patient identifier Social security number (SSN)  + date of birth (DOB), last 4 digits SSN + 
DOB, and SOUNDEX coding of last name 
ZIP code or census tract 5 or 9 digit number 
Behavioral risk history Two or more sex partners during previous 90 days, New sex partner during 
previous 90 days, Condom use during last intercourse, sex for money or 
drugs, Anonymous sex, IDU, crack use 
Pregnancy status Yes or No 
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